3-Hydroxy-2-quinoxalinecarboxylic acid

Discontinued Product

3-Hydroxy-2-quinoxalinecarboxylic acid (Cat. No. 0184) has been withdrawn from sale for commercial reasons.
Description: Broad spectrum EAA antagonist
Literature (5)

Biological Activity for 3-Hydroxy-2-quinoxalinecarboxylic acid

Broad spectrum antagonist at ionotropic glutamate receptors.

Technical Data for 3-Hydroxy-2-quinoxalinecarboxylic acid

M. Wt 190.16
Storage Store at RT
CAS Number 1204-75-7

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for 3-Hydroxy-2-quinoxalinecarboxylic acid

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for 3-Hydroxy-2-quinoxalinecarboxylic acid

References are publications that support the biological activity of the product.

Erez et al (1985) Anticonvulsant properties of 3-hydroxy-2-quinoxalinecarboxylic acid, a newly found antagonist of excitatory amino acids. Eur.J.Pharmacol. 110 31 PMID: 2861099

Frey et al (1988) 6,7-Dichloro-3-hydroxy-2-quinoxalinecarboxylic acid is a relatively potent antagonist at NMDA and kainate receptors. Neurosci.Lett. 91 194 PMID: 2847085

View Related Products by Product Action

View all Non-selective Ionotropic Glutamate Antagonists

Keywords: 3-Hydroxy-2-quinoxalinecarboxylic acid, 3-Hydroxy-2-quinoxalinecarboxylic acid supplier, Non-selective, Ionotropic, Glutamate, 0184, Tocris Bioscience

Citations for 3-Hydroxy-2-quinoxalinecarboxylic acid

Citations are publications that use Tocris products.

Currently there are no citations for 3-Hydroxy-2-quinoxalinecarboxylic acid.

Reviews for 3-Hydroxy-2-quinoxalinecarboxylic acid

There are currently no reviews for this product. Be the first to review 3-Hydroxy-2-quinoxalinecarboxylic acid and earn rewards!

Have you used 3-Hydroxy-2-quinoxalinecarboxylic acid?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Ion Channel Product Listing

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Pain Poster

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.